These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 19414315

  • 1. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S, Fukami T, Yagi H, Kuroki M, Yotsumoto F.
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [Abstract] [Full Text] [Related]

  • 2. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM, Allen GW, Bonner JA.
    J Clin Oncol; 2007 Sep 10; 25(26):4057-65. PubMed ID: 17827454
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of ligand-based targeting for the EGF system in cancer.
    Yotsumoto F, Sanui A, Fukami T, Shirota K, Horiuchi S, Tsujioka H, Yoshizato T, Kuroki M, Miyamoto S.
    Anticancer Res; 2009 Nov 10; 29(11):4879-85. PubMed ID: 20032451
    [Abstract] [Full Text] [Related]

  • 4. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
    Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F.
    Differentiation; 2007 Nov 10; 75(9):788-99. PubMed ID: 17608727
    [Abstract] [Full Text] [Related]

  • 5. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.
    Kataoka H.
    J Dermatol Sci; 2009 Dec 10; 56(3):148-53. PubMed ID: 19896805
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S, Grandis JR.
    J Clin Oncol; 2006 Jun 10; 24(17):2666-72. PubMed ID: 16763281
    [Abstract] [Full Text] [Related]

  • 7. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F, Lee HY.
    Drug Resist Updat; 2005 Oct 10; 8(5):298-310. PubMed ID: 16172017
    [Abstract] [Full Text] [Related]

  • 8. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O, Bozec A, Fischel JL, Milano G.
    Crit Rev Oncol Hematol; 2007 Apr 10; 62(1):53-61. PubMed ID: 17324578
    [Abstract] [Full Text] [Related]

  • 9. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J.
    Mol Cancer Res; 2007 Mar 10; 5(3):203-20. PubMed ID: 17374728
    [Abstract] [Full Text] [Related]

  • 10. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.
    Int J Biochem Cell Biol; 2007 Mar 10; 39(7-8):1416-31. PubMed ID: 17596994
    [Abstract] [Full Text] [Related]

  • 11. Emerging strategies for ErbB ligand-based targeted therapy for cancer.
    Tsujioka H, Yotsumoto F, Shirota K, Horiuchi S, Yoshizato T, Kuroki M, Miyamoto S.
    Anticancer Res; 2010 Aug 10; 30(8):3107-12. PubMed ID: 20871027
    [Abstract] [Full Text] [Related]

  • 12. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G, Ciardiello F, Gasparini G.
    Nat Clin Pract Oncol; 2008 Sep 10; 5(9):521-30. PubMed ID: 18594498
    [Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
    Wheatley-Price P, Shepherd FA.
    Curr Opin Oncol; 2008 Mar 10; 20(2):162-75. PubMed ID: 18300766
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor: a promising target in solid tumours.
    Laskin JJ, Sandler AB.
    Cancer Treat Rev; 2004 Feb 10; 30(1):1-17. PubMed ID: 14766123
    [Abstract] [Full Text] [Related]

  • 15. Targeting the EGFR and the PKB pathway in cancer.
    Klein S, Levitzki A.
    Curr Opin Cell Biol; 2009 Apr 10; 21(2):185-93. PubMed ID: 19216065
    [Abstract] [Full Text] [Related]

  • 16. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA, Lynch TJ.
    Oncologist; 2009 Apr 10; 14(4):399-411. PubMed ID: 19357226
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M, Saif MW.
    JOP; 2007 Jan 09; 8(1):4-15. PubMed ID: 17228128
    [Abstract] [Full Text] [Related]

  • 18. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A.
    Head Neck; 2008 Jun 09; 30(6):800-9. PubMed ID: 18429007
    [Abstract] [Full Text] [Related]

  • 19. EGFR as a target: rationale for therapy.
    Wujcik D.
    Semin Oncol Nurs; 2006 Feb 09; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [Abstract] [Full Text] [Related]

  • 20. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S, Ostman A, Rollman O.
    Arch Dermatol Res; 2008 Oct 09; 300(9):505-16. PubMed ID: 18446355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.